Skip to main content

Company History

Alcon History: Founding, Growth & Key Milestones

Founded 1945

When was Alcon founded?

Alcon was founded in 1945 by Robert Alexander and William Conner, making it 81 years old.

Founded
1945
Founders
Robert Alexander and William Conner
Milestones documented
12 (1945–2024)
Current CEO
David J. Endicott
Acquisitions
3
YearEvent
1945Founding in Fort Worth, Texas
1953Invention of the Drop-Tainer Bottle
1971Initial Public Offering on the NYSE
1977Acquisition by Nestlé S.A.
1994FDA Approval of AcrySof Intraocular Lens
2000Launch of Systane Lubricant Eye Drops
2008Novartis Acquires Initial 25% Stake from Nestlé
2011Novartis Completes Full Takeover and Merges CIBA Vision
2013Commercialization of Centurion Vision System
2019Historic $28 Billion Spin-Off from Novartis
2022Acquisitions of Aerie Pharmaceuticals and Ivantis
2024Net Sales Reach Record $9.82 Billion
Who founded Alcon?
Alcon was founded by Robert Alexander and William Conner.
When did Alcon start?
Alcon was founded in 1945.
How old is Alcon?
Alcon is 81 years old as of 2026.

Founding Story

Alcon's commercial genesis began with a shared vision between two Texas pharmacists who believed eye care deserved its own specialized manufacturing science. By merging the first syllables of their surnames—Robert Alexander and William Conner—they registered 'Alcon Laboratories' in 1945. While conventional drug manufacturers viewed ophthalmology as a tiny niche market secondary to systemic medications, Alexander and Conner focused exclusively on the human eye's delicate physiology. They discovered that ophthalmic solutions required precise pH balancing and isotonic stabilization to prevent severe stinging and tissue damage upon instillation. Working out of their small Fort Worth laboratory, they pioneered pre-mixed balanced salt solutions (BSS), which soon became the universal standard for irrigating eyes during cataract extractions. This unwavering devotion to surgical ophthalmology laid the groundwork for decades of biomaterial breakthroughs, transforming an independent Fort Worth pharmacy into an enterprise that would eventually touch more than 260 million patients across 140 countries annually.

Founders

Robert Alexander

Robert Alexander was an American pharmacist who co-founded Alcon Laboratories in Fort Worth, Texas in 1945 alongside William Conner. The duo combined their names (Alexander and Conner) to create the brand 'Alcon'. Alexander focused on sterile pharmaceutical compounding, recognizing that ophthalmologists lacked reliable, pre-mixed sterile solutions for eye surgery and infection treatment.

William Conner

William Conner was an American pharmacist and entrepreneur who co-founded Alcon Laboratories in 1945. Conner led early commercial operations, marketing vacuum-sealed saline and specialized eye medications directly to Dallas-Fort Worth physicians before expanding distribution nationwide across United States hospital clinics.

Key Milestones

1945

Founding in Fort Worth, Texas

Pharmacists Robert Alexander and William Conner open a neighborhood pharmacy and begin formulating sterile ophthalmic preparations.

1953

Invention of the Drop-Tainer Bottle

Alcon patents the first plastic squeeze bottle designed to dispense sterile eye drops drop-by-drop without air contamination.

1971

Initial Public Offering on the NYSE

Alcon lists its common shares publicly on the New York Stock Exchange, raising capital to build international manufacturing facilities.

1977

Acquisition by Nestlé S.A.

Swiss consumer and nutrition titan Nestlé acquires Alcon for approximately $280 million, providing extensive global resources.

1994

FDA Approval of AcrySof Intraocular Lens

Alcon introduces AcrySof, the world's first foldable acrylic biomaterial intraocular lens for modern cataract surgery.

2000

Launch of Systane Lubricant Eye Drops

Alcon commercializes the Systane dry eye franchise, utilizing advanced polymers to restore the eye's natural tear film.

2008

Novartis Acquires Initial 25% Stake from Nestlé

Swiss healthcare giant Novartis initiates a multi-stage buyout of Alcon, purchasing an initial 25% equity interest.

2011

Novartis Completes Full Takeover and Merges CIBA Vision

Novartis buys out remaining shares and merges its CIBA Vision contact lens unit into Alcon Laboratories.

2013

Commercialization of Centurion Vision System

Alcon launches its next-generation Centurion phacoemulsification console with Active Fluidics technology.

2019

Historic $28 Billion Spin-Off from Novartis

Novartis spins off 100% of Alcon shares to existing shareholders; Alcon lists independently on the SIX Swiss Exchange and NYSE.

2022

Acquisitions of Aerie Pharmaceuticals and Ivantis

Alcon acquires Aerie ($770M) and Ivantis ($475M) to expand into prescription glaucoma drugs and MIGS microstents.

2024

Net Sales Reach Record $9.82 Billion

Alcon reports record financial results driven by double-digit growth in Clareon IOLs and water-gradient contact lenses.

Major Acquisitions

Aerie Pharmaceuticals

2022

Ivantis, Inc.

2022

STAAR Surgical (Strategic Collaboration & Lens Assets)

2020

Keep researching Alcon

Alcon Company History FAQ

How did Alcon start in Fort Worth, Texas?

Alcon was founded in 1945 as a small retail compounding pharmacy by pharmacists Robert Alexander and William Conner. Seeing local eye doctors struggle with unsterile solutions, they began formulating specialized, sterile ophthalmic drops and invented the Drop-Tainer plastic bottle in 1953.

Why did Nestlé sell Alcon to Novartis?

Nestlé owned Alcon from 1977 until 2010, earning an extraordinary return on its original $280 million investment. Nestlé decided to divest Alcon in stages to Novartis for $51 billion between 2008 and 2011 to refocus its corporate capital purely on consumer food, beverage, and nutritional health.

When did Alcon become an independent company again?

Alcon became an independent publicly traded corporation on April 9, 2019, following a 100% tax-free spin-off from Novartis. It listed simultaneously on the SIX Swiss Exchange and the New York Stock Exchange under the ticker symbol ALC.

What was Alcon's most significant surgical breakthrough?

In 1994, Alcon introduced the AcrySof intraocular lens, the world's first foldable acrylic biocompatible lens. This allowed eye surgeons to insert an artificial lens through an incision smaller than 3 millimeters, revolutionizing outpatient cataract surgery.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.